74例上皮性卵巢癌患者BRCA基因突变状况及临床意义分析

doi:10.12280/gjfckx.20210068

摘要/Abstract

摘要：

目的： 统计上皮性卵巢癌（EOC）患者的胚系乳腺癌易感基因（BRCA）致病突变情况,分析其与临床病理特征的关系。方法： 收集2017年1月—2020年1月在天津市中心妇产科医院诊治的EOC患者的胚系BRCA 基因检测情况,并对BRCA基因致病突变与患者临床病理资料进行分析。结果： 74例EOC患者中BRCA1突变18例（24.3%）,BRCA2突变7例（9.5%）,主要突变方式包括框移突变15例,无义突变5例,突变主要集中在外显子编码区（CDS9和CDS10）。BRCA基因突变组和BRCA基因野生组患者的临床分期、组织病理学类型、淋巴结转移、血清CA-125水平、恶性肿瘤家族史进行比较,差异均无统计学意义（P>0.05）。BRCA基因突变组患者无复发生存期（RFS）长于BRCA基因野生组,差异有统计学意义（Z=-1.931,P=0.027）;2组患者遗传性乳腺癌卵巢癌综合征家族史（HBOC家族史）率比较差异有统计学意义（χ² =4.059,P=0.044）。结论： 有HBOC家族史的EOC患者的家系女性成员进行BRCA基因检测是筛查卵巢癌高危患者的有效手段。

关键词: 卵巢肿瘤, 遗传性乳腺癌和卵巢癌综合征, 基因,BRCA1, 基因,BRCA2, 突变, 上皮性卵巢癌

Abstract:

Objective： To analyze BRCA germline mutation in patients with epithelial ovarian cancer (EOC) and its relationship with clinical pathological features. Methods： The BRCA germline mutation results of 74 patients with EOC who received therapy at Tianjin Central Hospital of Gynecology Obstetrics from January 2017 to January 2020 were collected. Statistical analysis was performed on the relationship between BRCA mutation and clinical pathological features. Results： In 74 patients of EOC, the mutation rate of BRCA1 and BRCA2 were 24.3% and 9.5% respectively. The main mutation mode includes 15 cases of frame shift mutations and 5 cases of nonsense mutations. The mutations are mainly appears in the exon coding region (CDS9 and CDS10). There was no significant difference in the FIGO stage, pathological type, lymphatic metastasis status, serum levels of CA-125, family history of malignant tumor between BRCA-mutated patients and wild-type patients in this study (P>0.05). The recurrence-free survival (RFS) of patients with BRCA-mutated is longer than that of patients without BRCA-mutated, and the difference is statistically significant (Z=-1.931, P=0.027). Statistically significant correlations were observed between BRCA-mutated status and family history of hereditary breast cancer ovarian cancer syndrome (HBOC) ( χ ²=4.059, P=0.044). Conclusions： All female members of the family of EOC patients with family history of HBOC should undergo BRCA gene testing, which is an effective way to screen high-risk patients for ovarian cancer.

Key words: Ovarian neoplasms, Hereditary breast and ovarian cancer syndrome, Genes,BRCA1, Genes,BRCA2, Mutation, Epithelial ovarian cancer

饶阳, 李潇, 徐德欢, 朱雪萍, 曲芃芃. 74例上皮性卵巢癌患者BRCA基因突变状况及临床意义分析[J]. 国际妇产科学杂志, 2021, 48(3): 351-355.

RAO Yang, LI Xiao, XU De-huan, ZHU Xue-ping, QU Peng-peng. Analysis of BRCA Gene Mutation Status and Clinical Significance in 74 Patients with Epithelial Ovarian Cancer[J]. Journal of International Obstetrics and Gynecology, 2021, 48(3): 351-355.

图/表 3

参考文献 20

[1]	Marchetti C, Muzii L, Romito A, et al. First-line treatment of women with advanced ovarian cancer:focus on bevacizumab[J]. Onco Targets Ther, 2019,12:1095-1103. doi: 10.2147/OTT.S155425. doi: 10.2147/OTT.S155425
[2]	Canadas A, Santos M, Nogueira A, et al. Canine mammary tumor risk is associated with polymorphisms in RAD51 and STK11 genes[J]. J Vet Diagn Invest, 2018,30(5):733-738. doi: 10.1177/1040638718789231. doi: 10.1177/1040638718789231
[3]	胡丹, 杨永秀, 王欣, 等. 同源重组修复基因在卵巢癌中的研究进展[J]. 国际妇产科学杂志, 2019,46(4):453-456. doi: 10.3969/j.issn.1674-1870.2019.04.022. doi: 10.3969/j.issn.1674-1870.2019.04.022
[4]	Jiang X, Li X, Li W, et al. PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms[J]. J Cell Mol Med, 2019,23(4):2303-2313. doi: 10.1111/jcmm.14133. doi: 10.1111/jcmm.14133 pmid: 30672100
[5]	Madariaga A, Lheureux S, Oza AM. Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations[J]. Cancers(Basel), 2019,11(3):416. doi: 10.3390/cancers11030416. doi: 10.3390/cancers11030416
[6]	陈振波, 孟元光. BRCA基因与卵巢癌诊治相关的研究进展[J]. 国际妇产科学杂志, 2021,48(2):144-148. doi: 10.12280/gjfckx.20200655. doi: 10.12280/gjfckx.20200655
[7]	Manchana T, Phoolcharoen N, Tantbirojn P. BRCA mutation in high grade epithelial ovarian cancers[J]. Gynecol Oncol Rep, 2019,29:102-105. doi: 10.1016/j.gore.2019.07.007. doi: 10.1016/j.gore.2019.07.007 pmid: 31467961
[8]	Wu X, Wu L, Kong B, et al. The First Nationwide Multicenter Prevalence Study of Germline BRCA1 and BRCA2 Mutations in Chinese Ovarian Cancer Patients[J]. Int J Gynecol Cancer, 2017,27(8):1650-1657. doi: 10.1097/IGC.0000000000001065. doi: 10.1097/IGC.0000000000001065
[9]	Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer[J]. N Engl J Med, 2018,379(26):2495-2505. doi: 10.1056/NEJMoa1810858. doi: 10.1056/NEJMoa1810858
[10]	Jayson GC, Kohn EC, Kitchener HC, et al. Ovarian cancer[J]. Lancet, 2014,384(9951):1376-1388. doi: 10.1016/SO140-6736(13)62146-7. doi: 10.1016/SO140-6736(13)62146-7
[11]	Essel KG, Moore KN. Niraparib for the treatment of ovarian cancer[J]. Expert Rev Anticancer Ther, 2018,18(8):727-733. doi: 10.1080/14737140.2018.1490180. doi: 10.1080/14737140.2018.1490180
[12]	Coleman RL, Fleming GF, Brady MF, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer[J]. N Engl J Med, 2019,381(25):2403-2415. doi: 10.1056/NEJMoa1909707. doi: 10.1056/NEJMoa1909707
[13]	Li A, Xie R, Zhi Q, et al. BRCA germline mutations in an unselected nation wide cohort of Chinese patients with ovarian cancer and healthy controls[J]. Gynecol Oncol, 2018,151(1):145-152. doi: 10.1016/j.ygyno.2018.07.024. doi: 10.1016/j.ygyno.2018.07.024
[14]	Bu H, Chen J, Li Q, et al. BRCA mutation frequency and clinical features of ovarian cancer patients: A report from a Chinese study group[J]. J Obstet Gynaecol Res, 2019,45(11):2267-2274. doi: 10.1111/jog.14090. doi: 10.1111/jog.14090
[15]	Rudaitis V, Zvirblis T, Kanopiene D, et al. BRCA1/2 mutation status is an independent factor of improved survival for advanced (stage III-IV) ovarian cancer[J]. Int J Gynecol Cancer, 2014,24(8):1395-1400. doi: 10.1097/IGC.0000000000000247. doi: 10.1097/IGC.0000000000000247
[16]	刘伟玲, 王志中, 赵九洲, 等. 散发性高级别卵巢浆液性癌的BRCA基因突变及其临床意义[J]. 中华妇产科杂志, 2017,52(1):26-31. doi: 10.3760/cma.j.issn.0529-567x.2017.01.007. doi: 10.3760/cma.j.issn.0529-567x.2017.01.007
[17]	吴焕文, 梁智勇. 基于下一代测序技术的BRCA1/2基因检测指南(2019版)[J]. 中华病理学杂志, 2019,48(9):670-677. doi: 10.3760/cma.j.issn.0529?5807.2019.09.002. doi: 10.3760/cma.j.issn.0529?5807.2019.09.002
[18]	Porcu E, Cillo GM, Cipriani L, et al. Impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcomes in young women with breast cancer[J]. J Assist Reprod Genet, 2020,37(3):709-715. doi: 10.1007/s10815-019-01658-9. doi: 10.1007/s10815-019-01658-9
[19]	Liu Y, Lu LY. BRCA1 and homologous recombination: implications from mouse embryonic development[J]. Cell Biosci, 2020,10:49. doi: 10.1186/s13578-020-00412-4. doi: 10.1186/s13578-020-00412-4
[20]	刘晓时, 狄文. BRCA基因突变女性携带者生育力保存研究进展[J]. 国际妇产科学杂志, 2021,48(1):71-74. doi: 10.12280/gjfckx.20200287. doi: 10.12280/gjfckx.20200287

组别	n	年龄（岁）	FIGO分期		病理类型			淋巴结转移		HBOC家族史		恶性肿瘤家族史
组别	n	年龄（岁）	Ⅰ~Ⅱ	Ⅲ~Ⅳ	高级别浆液性	黏液性	其他类型*	有	无	有	无	有	无
突变组	25	54.2±9.3	7（28.0）	18（72.0）	23（92.0）	0（0.0）	2（8.0）	16（64.0）	9（36.0）	10（40.0）	15（60.0）	15（60.0）	10（40.0）
野生组	49	52.5±8.1	13（26.5）	36（73.5）	39（79.6）	2（4.1）	8（16.3）	21（42.9）	28（57.1）	9（18.4）	40（81.6）	26（53.1）	23（46.9）
t或χ²		0.658	0.018			7.144		2.960		4.059		0.323
P		0.355	0.893			0.128		0.085		0.044		0.570

组别	n	年龄（岁）	FIGO分期		病理类型			淋巴结转移		HBOC家族史		恶性肿瘤家族史
组别	n	年龄（岁）	Ⅰ~Ⅱ	Ⅲ~Ⅳ	高级别浆液性	黏液性	其他类型*	有	无	有	无	有	无
突变组	25	54.2±9.3	7（28.0）	18（72.0）	23（92.0）	0（0.0）	2（8.0）	16（64.0）	9（36.0）	10（40.0）	15（60.0）	15（60.0）	10（40.0）
野生组	49	52.5±8.1	13（26.5）	36（73.5）	39（79.6）	2（4.1）	8（16.3）	21（42.9）	28（57.1）	9（18.4）	40（81.6）	26（53.1）	23（46.9）
t或χ²		0.658	0.018			7.144		2.960		4.059		0.323
P		0.355	0.893			0.128		0.085		0.044		0.570